Heparin-induced thrombocytopenia, Heparin, Internal medicine, Platelet and Anticoagulant are his primary areas of study. His studies deal with areas such as Fondaparinux, Pre- and post-test probability, Intensive care medicine, Serology and Danaparoid as well as Heparin-induced thrombocytopenia. Theodore E. Warkentin interconnects Platelet activation, Thrombosis and Immunology in the investigation of issues within Heparin.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Adverse drug reaction, Surgery and Cardiology. His studies in Platelet integrate themes in fields like Hematology, Fc receptor, Monoclonal antibody and Pathology. His Anticoagulant research is multidisciplinary, relying on both Anesthesia and Intensive care.
His primary areas of investigation include Heparin-induced thrombocytopenia, Heparin, Internal medicine, Immunology and Platelet. His Heparin-induced thrombocytopenia research is multidisciplinary, incorporating perspectives in Warfarin, Fondaparinux, Pharmacology, Low molecular weight heparin and Danaparoid. His Heparin research includes themes of Platelet activation, Thrombosis, Anesthesia and Anticoagulant.
His research investigates the connection between Thrombosis and topics such as Disseminated intravascular coagulation that intersect with issues in Coagulopathy. His Internal medicine research integrates issues from Gastroenterology, Surgery and Cardiology. He combines subjects such as Molecular biology, Cardiac surgery, Biochemistry and Monoclonal antibody with his study of Platelet.
Theodore E. Warkentin mainly investigates Heparin-induced thrombocytopenia, Heparin, Internal medicine, Thrombosis and Platelet. His Heparin-induced thrombocytopenia study is concerned with the field of Immunology as a whole. His Heparin research incorporates elements of Platelet activation, Anesthesia and Immunoassay, Antibody.
Theodore E. Warkentin has included themes like Gastroenterology and Cardiology in his Internal medicine study. His Thrombosis study combines topics from a wide range of disciplines, such as Disseminated intravascular coagulation, Gangrene and Warfarin. His studies deal with areas such as Cardiac surgery and Incidence as well as Platelet.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
Theodore E. Warkentin;Mark N. Levine;Jack Hirsh;Peter Horsewood.
The New England Journal of Medicine (1995)
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Jack Hirsh;Theodore E. Warkentin;Stephen G. Shaughnessy;Sonia S. Anand.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
Andreas Greinacher;Thomas Thiele;Theodore E. Warkentin;Karin Weisser.
The New England Journal of Medicine (2021)
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
Jack Hirsh;Theodore E. Warkentin;Robert Raschke;Christopher Granger.
Temporal aspects of heparin-induced thrombocytopenia.
Theodore E. Warkentin;John G. Kelton.
The New England Journal of Medicine (2001)
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Theodore E. Warkentin;Andreas Greinacher.
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Theodore E. Warkentin;Andreas Greinacher;Andreas Koster;A. Michael Lincoff.
A 14-year study of heparin-induced thrombocytopenia
Theodore E. Warkentin;John G. Kelton;John G. Kelton.
The American Journal of Medicine (1996)
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
G. K. Lo;D. Juhl;T. E. Warkentin;C. S. Sigouin.
Journal of Thrombosis and Haemostasis (2006)
Impact of the patient population on the risk for heparin-induced thrombocytopenia
Theodore E. Warkentin;Jo-Ann I. Sheppard;Peter Horsewood;Patricia J. Simpson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: